ESPR earnings analysis
What we found in ESPR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Esperion Therapeutics, Inc. reported a revenue of $43.4 million in Q1 2026, up 24.3% from $34.9 million in Q1 2025, with significant growth registered in both product and collaboration revenues. Operating loss improved to $6.6 million from a loss of $22.1 million in the prior year, signifying effective cost management despite ongoing challenges. However, the company continues to face liquidity pressures as cash used in operating activities reached $27.7 million during the quarter.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Revenue increased by $8.5 million to $43.4 million in Q1 2026 from $34.9 million in Q1 2025.
- Operating Loss Reduced
- Improvement in operating loss to $6.6 million compared to $22.1 million in the same quarter last year.
- Cash Reserves
- As of March 31, 2026, cash and cash equivalents totaled $156.2 million, providing a solid liquidity base.
- Cost Management Success
- Research and development costs decreased by $3.6 million to $9.0 million in Q1 2026, aiding margin enhancements.
- Collaboration Revenue Growth
- Collaboration revenue rose to $36.7 million in Q1 2026, up from $30.1 million in Q1 2025, reflecting strength in partnerships.
- Merger with Corstasis Completed
- The $75 million acquisition of Corstasis was finalized on April 2, 2026, potentially advancing product offerings.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Operating Losses
- Esperion has reported net losses continuously, posting a $25.2 million loss in Q1 2026 vs. $40.5 million in Q1 2025.
- Material Weakness in Internal Controls
- A material weakness in internal control was noted, affecting financial reporting accuracy.
- High Interest Expenses
- Interest expense increased to $19.8 million in Q1 2026, constraining cash flow and profitability.
What they reported.
What the company itself reported, taken out of the document.
- Segment
- Product Sales
- Segment
- Collaboration Revenue
What they said about what is next.
Management expressed that current cash resources and projected product revenues should sustain operations for the foreseeable future.
The filing reads better than the one before it.
What came before.
- 10-K · March 10, 2026
- Esperion reports accelerating commercial traction: FY25 total revenue grew 21% year-over-year to $403.1 million, driven by U.S. net product revenue of $159.6 million (up 38% Y/Y) and a strong Q4 2025 total quarter of…
- 10-Q · November 6, 2025
- Esperion reported Q3 2025 revenue of $87.3M (up from $51.6M in Q3 2024) driven by higher collaboration revenue and product sales, but recorded a net loss of $31.3M (EPS -$0.16). Gross margin improved (revenues $87.3M…
- 10-Q · November 7, 2024
- Esperion reported Q3 revenue of $51.632M, up from $33.969M in Q3 2023, driven by higher product sales ($31.106M vs $20.251M) and higher collaboration revenue ($20.526M vs $13.718M). Gross margin expanded to ~66.6% (COGS…
- 10-Q · May 7, 2024
- Esperion reported a step-change quarter with total revenues of $137,735 (in thousands) in Q1 2024 versus $24,329 (in thousands) in Q1 2023, driven by a $112,979 (in thousands) collaboration milestone and higher product…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ESPR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever